Program Project #1 will use the EBV model of persistent viral infection te characterize the lineage relationship between effector and memory responses and the factors that influence the evolution ef antigen- specific CDS+ T cell responses into the memory CD8+ T cell repertoire. Work outlined in this project addresses the collective hypotheses that virus-specific CD8+ T cell repertoires change quantitatively and qualitatively over time following acute infection, and that differences in virus-specific CDS+ T cell repertoires may influence the control of viral replication, viral sequence evolution, and disease pathogenesis. Changes in the EBV-specific CD8+ T cell repertoire over time may be based en inherent properties of EBV-specific CDS+ T cell clones (specificity, TCR usage, avidity, genome-wide transcriptional profiles), prior infections and ongoing antigenic exposure.
Specific Aim 1 will use'TCR CDR3a and p sequencing te define the relationship between the EBV epitope-specific TCR repertoires at serial time points from the acute through the memory phases ef the T cell response.
Specific Aim 2 will define genome-wide expression profiles in EBV epitope-specific CD8+ T cells during the acute phase of the T cell response and CDS+ T cell persistence into the memory pool in order te examine whether specific gene expression signatures correlate with the size ofthe EBV epitope-specific CD8+ T cell response during AIM, persistence er non-persistence of the EBV epitope-specific CD8+ T cell response, control ef EBV replication, and/or AIM symptoms in primary infection.
Specific Aim 3 will use novel deep sequencing methods to define EBV founder populations and track EBV sequence evolution in oropharyngeal secretions and peripheral bleed B cells ever time following infection. Characterization of intra-host EBV genetic sequence variability should improve our understanding ef anatomical sites ef EBV replication and persistence and should better define factors (viral replication, repeated infections, immune selective pressures) that contribute te EBV sequence diversity over time. Project 1 integrates experimentally and conceptually with the proposed characterization of cress-reactive CDS+ T cells in Project 2 (Selin) and will use the services ef all 3 Ceres.
The proposed studies along with those in Project 2, will provide insight inte factors that control the evolution ef human antiviral CD8+ T cell responses from the acute effector phase into long-term memory and how antigen-specific or cross-reactive CD8+ T cells may contribute to either viral control or disease. Ultimately, we hope that they will help to inform the development ef antiviral vaccines that afford long-term protection against infection or disease, while minimizing the potential adverse effects of these vaccines. PROJECT/PERFORIVIANCE SITE(S) (if additional space is needed, use Project/Performance Project/
|Gil, Anna; Kenney, Laurie L; Mishra, Rabinarayan et al. (2015) Vaccination and heterologous immunity: educating the immune system. Trans R Soc Trop Med Hyg 109:62-9|
|Gil, Anna; Yassai, Maryam B; Naumov, Yuri N et al. (2015) Narrowing of human influenza A virus-specific T cell receptor Î± and Î² repertoires with increasing age. J Virol 89:4102-16|
|Greenough, Thomas C; Straubhaar, Juerg R; Kamga, Larisa et al. (2015) A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection. J Immunol 195:4185-97|
|Renzette, Nicholas; Somasundaran, Mohan; Brewster, Frank et al. (2014) Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids. J Virol 88:3744-55|
|Chen, Alex T; Cornberg, Markus; Gras, Stephanie et al. (2012) Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog 8:e1002633|
|Tracy, Sean I; Kakalacheva, Kristina; Lunemann, Jan D et al. (2012) Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol 86:12330-40|
|O'Bryan, Joel M; Potts, James A; Bonkovsky, Herbert L et al. (2011) Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One 6:e20922|
|Selin, Liisa K; Wlodarczyk, Myriam F; Kraft, Anke R et al. (2011) Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity 44:328-47|
|Welsh, Raymond M; Che, Jenny W; Brehm, Michael A et al. (2010) Heterologous immunity between viruses. Immunol Rev 235:244-66|
|Greenough, Thomas C; Campellone, Shalyn C; Brody, Robin et al. (2010) Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage. PLoS One 5:e12926|
Showing the most recent 10 out of 33 publications